Celldex Therapeutics, Inc. Balance Sheet
CLDX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 15 fiscal years. All figures from audited SEC 10-K filings.
Celldex Therapeutics, Inc. had $583M in total assets and $527M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.9M | $28.4M | $34.8M | $29.4M | $39.1M | $43.8M | $11.2M | $42.5M | $40.3M | $42.5M | $72.1M | $28.0M | $169.4M | $24.9M | $57.0M |
| Current Assets | $534.7M | $747.2M | $431.7M | $317.7M | $410.8M | $197.8M | $66.7M | $99.1M | $144.8M | $195.6M | $294.9M | $205.0M | $305.2M | $85.1M | $54.7M |
| PP&E (Net) | $5.3M | $4.3M | $4.1M | $3.7M | $3.6M | $3.8M | $4.0M | $6.1M | $10.4M | $13.2M | $11.5M | $10.5M | $10.0M | $7.2M | $9.1M |
| Goodwill | - | - | - | - | - | - | - | - | $91.0M | $91.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M |
| Total Assets | $583.0M | $792.3M | $465.6M | $352.7M | $444.7M | $235.8M | $122.9M | $155.8M | $315.6M | $383.4M | $337.6M | $248.0M | $347.1M | $125.5M | $98.0M |
| Current Liabilities | $51.0M | $39.5M | $31.1M | $18.6M | $16.5M | $14.2M | $11.6M | $12.6M | $27.7M | $35.2M | $30.2M | $24.5M | $20.4M | $17.7M | $14.3M |
| Shareholders' Equity | $527.2M | $747.0M | $429.2M | $326.2M | $419.5M | $209.4M | $94.0M | $265.4M | $236.4M | $265.4M | $290.1M | $211.7M | $319.8M | $95.8M | $73.8M |